Fig. 1

Consecutive MSC infusion alleviated Dox-induced cardiotoxicity. A. Experimental scheme of this study design. B. Survival analysis of mice administrated with PBS (Control), Dox/PBS, Dox/Single dose, or Dox/Consecutive doses (n = 15). P < 0.05, Dox/Consecutive doses vs Dox/PBS. Data were analyzed by two-sided Kaplan–Meier estimator. C. Quantitative proportion of bodyweight loss in mice administrated with PBS (Control), Dox/PBS, Dox/Single dose, or Dox/Consecutive doses, on days 0, 4, 7, 10, and 14 (n = 4). ^*P < 0.05 vs Dox/PBS, ^#P < 0.05 vs Dox/Single dose. D and E. Representative immunofluorescence images of ventricles and statistics of cell cross-sectional area (n = 5) in mice administrated with PBS (Control), Dox/PBS, Dox/Single dose, or Dox/Consecutive doses. Scale bar, 100 μm. ^****P < 0.0001 vs Control, ^####P < 0.0001 vs Dox/PBS, ^&&&&P < 0.0001 vs Dox/Single dose. F and G. Representative ventricular structure and quantitative vacuolization (n = 5) in mice administrated with PBS (Control), Dox/PBS, Dox/Single dose or Dox/Consecutive doses. Scale bar, 50 μm. ^****P < 0.0001 vs Control, ^####P < 0.0001 vs Dox/PBS, ^&&P < 0.01 vs Dox/Single dose. H. Representative echocardiographic images (M-mode) of mice administered with PBS (Control), Dox/PBS, Dox/Single dose or Dox/Consecutive doses on days 0, 7 and 14. I and J. Statistics of the left ventricular ejection fraction (EF) and fractional shortening (FS) in each group on days 0, 7 and 14 (n = 5). ^*P < 0.05 vs Dox/PBS, ^#P < 0.05 vs Dox/Single dose. K and L. Serum levels of brain natriuretic peptide (BNP) and troponin T (TnT) in mice administrated with PBS (Control), Dox/PBS, Dox/Single dose or Dox/Consecutive doses on days 7 and 14 (n = 5). ^***P < 0.001, ^****P < 0.0001 vs Control, ^##P < 0.01, ^###P < 0.001, ^####P < 0.0001 vs Dox/PBS, ^&&&P < 0.001, ^&&&&P < 0.0001 vs Dox/Single doses. Data were analyzed by one-way ANOVA followed by Bonferroni post hoc test, unless specifically indicated